JP2024534639A5 - - Google Patents
Info
- Publication number
- JP2024534639A5 JP2024534639A5 JP2024518996A JP2024518996A JP2024534639A5 JP 2024534639 A5 JP2024534639 A5 JP 2024534639A5 JP 2024518996 A JP2024518996 A JP 2024518996A JP 2024518996 A JP2024518996 A JP 2024518996A JP 2024534639 A5 JP2024534639 A5 JP 2024534639A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- tada
- hbv
- sequence
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163248938P | 2021-09-27 | 2021-09-27 | |
| US63/248,938 | 2021-09-27 | ||
| US202263357623P | 2022-06-30 | 2022-06-30 | |
| US63/357,623 | 2022-06-30 | ||
| US202263371634P | 2022-08-16 | 2022-08-16 | |
| US63/371,634 | 2022-08-16 | ||
| PCT/US2022/077105 WO2023049935A1 (en) | 2021-09-27 | 2022-09-27 | Compositions and methods for treating hepatitis b virus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534639A JP2024534639A (ja) | 2024-09-20 |
| JP2024534639A5 true JP2024534639A5 (enExample) | 2025-10-06 |
Family
ID=85721334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518996A Pending JP2024534639A (ja) | 2021-09-27 | 2022-09-27 | Ｂ型肝炎ウイルス感染症を治療するための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240294914A1 (enExample) |
| EP (1) | EP4408986A4 (enExample) |
| JP (1) | JP2024534639A (enExample) |
| KR (1) | KR20240111821A (enExample) |
| CN (1) | CN119013394A (enExample) |
| AU (1) | AU2022353130A1 (enExample) |
| CA (1) | CA3233413A1 (enExample) |
| WO (1) | WO2023049935A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202503061A (zh) * | 2023-06-16 | 2025-01-16 | 大陸商益杰立科（上海）生物科技有限公司 | 靶向ｂ型肝炎病毒基因的表觀編輯工具 |
| WO2025126049A2 (en) * | 2023-12-11 | 2025-06-19 | Crispr Therapeutics Ag | Multiplex gene editing |
| WO2026124637A1 (zh) * | 2024-12-13 | 2026-06-18 | 益杰立科(上海)生物科技有限公司 | 靶向乙型肝炎病毒基因的表观编辑工具 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2966170A1 (en) * | 2014-07-10 | 2016-01-13 | Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - | HBV inactivation |
| CA3001351A1 (en) * | 2015-10-21 | 2017-04-27 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating hepatitis b virus |
| KR101842131B1 (ko) * | 2016-09-05 | 2018-03-27 | 연세대학교 산학협력단 | Hbv를 표적으로 하는 유전자 가위 및 이를 포함하는 hbv 감염 치료용 조성물 |
| MA51787A (fr) * | 2018-02-05 | 2020-12-16 | Vertex Pharma | Substances et méthodes de traitement d'hémoglobinopathies |
| JP7679309B2 (ja) * | 2019-05-10 | 2025-05-19 | ビーム セラピューティクス インク． | Ｂ型肝炎を治療するための組成物及び方法 |
-
2022
- 2022-09-27 KR KR1020247012453A patent/KR20240111821A/ko active Pending
- 2022-09-27 AU AU2022353130A patent/AU2022353130A1/en active Pending
- 2022-09-27 EP EP22873940.5A patent/EP4408986A4/en active Pending
- 2022-09-27 JP JP2024518996A patent/JP2024534639A/ja active Pending
- 2022-09-27 CN CN202280077560.XA patent/CN119013394A/zh active Pending
- 2022-09-27 CA CA3233413A patent/CA3233413A1/en active Pending
- 2022-09-27 WO PCT/US2022/077105 patent/WO2023049935A1/en not_active Ceased
-
2024
- 2024-03-26 US US18/617,539 patent/US20240294914A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7698828B2 (ja) | Ｒｎａを編集する方法および組成物 | |
| JP2025170240A5 (enExample) | ||
| JP2022546608A5 (enExample) | ||
| JP2024038326A5 (enExample) | ||
| US20180236103A1 (en) | Crispr/cas-related methods and compositions for treating hepatitis b virus | |
| JP2025102768A5 (enExample) | ||
| JP2021523736A5 (enExample) | ||
| JP2024038327A5 (enExample) | ||
| JP2022519882A5 (enExample) | ||
| EP2966170A1 (en) | HBV inactivation | |
| US11499151B2 (en) | Methods and systems for analyzing guide RNA molecules | |
| TW202028466A (zh) | 編輯RNAs的方法以及組成物 | |
| JP2022532139A5 (enExample) | ||
| JP2024520528A5 (enExample) | ||
| JP2022533673A5 (enExample) | ||
| JP2024501246A5 (enExample) | ||
| Zhou et al. | Efficient silencing of hepatitis B virus S gene through CRISPR‐mediated base editing | |
| US12390538B2 (en) | Compositions and methods for epigenetic regulation of HBV gene expression | |
| JP2024506375A5 (enExample) | ||
| US20240294914A1 (en) | Compositions and methods for treating hepatitis b virus infection | |
| CN120464655A (zh) | 一种人工核酸分子 | |
| JP2024546841A5 (enExample) | ||
| JP2024529108A5 (enExample) | ||
| US5856085A (en) | Compositions and methods of developing oligonucleotides and oligonucleotide analogs having antiviral activity | |
| CA3147641A1 (en) | Compositions and methods for modulating apolipoprotein b (apob) gene expression |